FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy

1Tumour-associated macrophages (TAMs) are highly abundant in a range of solid tumours. Whilst some clinical data indicates an association with reduced patient survival,, others suggest specific subsets of macrophages can improve patient outcomes,. These disparities may be due to macrophages having both pro- and anti-tumourigenic effects. Macrophage nomenclature has evolved over recent years to take account of these differing phenotypes, and although some debate still remains, it is largely accepted that most TAMs lie on a spectrum that can encompass features of both classically activated ‘M1’ macrophages, exhibiting immune-stimulatory functions, and alternatively activated ‘M2’ immune-suppressive macrophages–. Experimental evidence demonstrates that TAMs are often skewed towards a pro-tumourigenic phenotype. Tumour microenvironmental stimuli, including tumour-derived cytokines, can polarise macrophages towards an M2 phenotype,, promoting tumour growth through mechanisms including angiogenesis, proliferation, local invasion, metastatic potential and immune escape,. Macrophages also mediate resistance to therapy including radiotherapy, and irradiation can augment angiogenic and pro-tumourigenic macrophage phenotypes,–. Recent data suggest a key role for macrophages in modulating the host adaptive immune response, primarily via suppressive effects on CD8+ T lymphocytes.

2In this study, we demonstrate that fibroblast growth factor 2 (FGF2) plays a pivotal role in shifting TAMs towards a pro-tumourigenic, M2-like phenotype in the tumour microenvironment. FGF2 is one member of a family of related proteins (FGFs) that exert mitogenic activity by binding to FGF receptors (FGFR)–. Of these receptors, FGF2 has the highest affinity for FGFR1, 2 and 3b. FGF2 has many isoforms, generated by the use of alternative translational start sites. The lowest molecular weight isoform, FGF2LMW, is the only secreted form,, and is a highly potent angiogenic molecule,,. FGF2LMW also affects the response to injury in skin, nerve and cartilage,,,,. The higher molecular weight forms of FGF2 are often nuclear in location and can regulate transcription independently of FGFRs. In previous work, we found that FGF2LMW was highly expressed by myeloid cells in colorectal cancer (CRC) liver metastases. Blocking FGF2 with an antibody delayed growth of murine CRC liver metastases through vascular renormalisation.

3Here, we show that tumours regressed in mice genetically deficient in FGFLMW(Fgf2LMW−/−) while shifting TAM polarisation. Cancer cells failed to develop substantial liver metastases or subcutaneous tumours in Fgf2LMW−/− mice. Fgf2LMW−/− TAMs were more inflammatory, (M1-like) than in C57Bl6 wildtype (WT) mice, and subcutaneous tumour regression was T cell-dependent. In WT mice, TAMs were the major source of FGF2, and were the only immune cell to abundantly express FGFR1 and 2. FGF2 has been reported to be induced in irradiated human tumours– raising the possibility that FGF2 might be a useful therapeutic target for patients who have received radiotherapy. Accordingly, we examined the effect of FGF2 on the irradiation response, and found that a blocking antibody to FGF2 in combination with radiotherapy reduced or even eliminated tumour regrowth in association with an increase in the TAM iNOS+/CD206+ ratio (also called a M1/M2 ratio).

4To ask whether liver metastases would be constrained in Fgf2LMW−/− mice as they were by blocking anti-FGF2 antibody,, we examined the growth of liver metastases in Fgf2LMW−/− mice. After intrasplenic injection of the murine CRC cell line, MC38 or the pancreatic cancer cell line, KPC into WT or Fgf2LMW−/− mice, Fgf2LMW−/− mice had significantly less liver tumour burden (Fig. 1a) with macroscopic colonies evident in only 3 of 8 (37%) and 2 of 6 (33%) Fgf2LMW−/− mice injected with MC38 and KPC cells respectively compared with 100% in WT mice. Histological analysis showed increased immune infiltration in Fgf2LMW−/− mice, particularly at the metastasis-liver border (arrows, Fig. 1b).

5After subcutaneous injection MC38(1 × 104 cells) and KPC (2 × 105 cells) tumours reached endpoint by day 21 in WT mice, yet only 1 of 10 (10%) MC38 and 5 of 8 (63%) KPC tumours in Fgf2LMW−/− mice reached endpoint by day 120 (500 mm3, Fig. 1c–f). Initially tumours from both cell lines grew in Fgf2LMW−/− mice (albeit significantly slower than in WT mice, Fig. 1d, f), then growth plateaued, and tumours either regressed completely or resumed growth after a delay (between day 40 and 70; Fig. 1d, f). This growth pattern also occurred with a cell line of non-gastrointestinal origin, the lung carcinoma cell line, LLC in Fgf2LMW−/− mice (Supplementary Fig. 1a, b). Histological analysis of subcutaneous tumours revealed increased immune infiltration in tumours in Fgf2LMW−/− mice (Fig. 1g), similar to the liver metastasis model suggesting that FGF2LMW might mediate tumour immunity.

6To investigate the immune infiltration in tumours in Fgf2LMW−/− mice, we collected immune cells from tumours in WT and Fgf2LMW−/− mice at day 10 after inoculation for analysis by flow cytometry (Fig. 1h). Tumours in Fgf2LMW−/− mice contained increased proportions of CD4+ and CD8+ T cells. The percentages of F4/80+ macrophages were unaltered and there was an increase in CD11b+Gr-1HIGH granulocytes (Fig. 1h). Immunohistochemistry confirmed that subcutaneous tumours and liver metastases in Fgf2LMW−/− mice had increased infiltration by T cells (CD3+ cells, both CD4 and CD8), which extended into the clusters of tumour cells (Fig. 1i).

7We characterised changes in cytokine and chemokine expression by qPCR of tumour lysates. Tumours from the Fgf2LMW−/− mice had increased levels of many CCL and CXCL chemokines, and pro-inflammatory cytokines, many characteristically expressed by myeloid cells (Supplementary Fig. 2). These data provide evidence of a shift towards the inflammatory spectrum in tumours in Fgf2LMW−/− mice.

8Because of the tumour regression and increased proportion of T cells in tumours of Fgf2LMW−/− mice, we asked whether depletion of T cells would rescue tumour growth in Fgf2LMW−/− mice (Fig. 1j). T cells were depleted using anti-CD3 antibody. In PBS treated Fgf2LMW−/− mice, tumours began to regress by day 8, consistent with the experiments shown above. In contrast, T cell depletion in Fgf2LMW−/− mice led to rapid tumour growth. Overall these studies demonstrate that T cells mediate tumour regression in Fgf2LMW−/− mice. However, T cell depletion resulted in less rapid tumour growth in Fgf2LMW−/− mice than in WT mice implicating a component of T cell independent alteration in growth (Fig. 1j).

9In addition, the absence of FGF2LMW led to altered cytokine expression in CD4+ and CD8+ T cells. CD4+ and CD8+ T cells isolated from tumours of Fgf2LMW−/− mice had increased RNA expression of Il6, Il12, and Il17 compared with T cells isolated from WT mice. CD4+ T cells also had increased Ifnγ and CD8+ T cells had increased Il13. Both showed enhanced expression of the proliferation marker Ki67 (Fig. 1k). Thus, both CD4+ and CD8 T cells showed evidence of increased activation and proliferation in tumours of Fgf2LMW−/− mice.

10Since an immune response was required for tumour regression in Fgf2LMW−/− mice, we asked which immune cells expressed FGF2 receptors. Despite the involvement of T cells in tumour regression, we failed to detect FGFR1 or 2 on T cells or other immune cell types from either naïve mice or from tumour bearing mice, except TAMs. Over 85% of TAMs expressed FGFR1 and ~65% expressed FGFR2. Less than 5% of myeloid cells from naïve spleens expressed either receptor (Fig. 2a, b). TAMs also expressed more Fgfr1, 3 and 4 RNA and substantially more Fgfr2 RNA than naïve bone marrow derived-macrophages (BMDM) with over a 100-fold increase in Fgfr2 (Fig. 2c). Thus macrophages were the main immune cell subtype within tumours that might be expected to respond directly to FGF2.

11Since BMDM themselves expressed little Fgfr RNA, we asked whether tumour cells could directly affect FGFR expression by macrophages. We co-cultured BMDM with tumour cells for 24 h and with irradiated tumour cells, as tumour irradiation is known to influence macrophage activation,–. Co-culture of BMDM with MC38 or KPC tumour cells led to increased expression of FGFR1 and 2 on BMDM and this increase was greater if the tumour cells had been irradiated (Fig. 2d, e). Further conditioned medium (CM) from MC38 cancer cells was sufficient to induce Fgfr1 and Fgfr2 although with a longer time course (Fig. 2f). We then asked whether induction of macrophage polarisation using LPS, a canonical stimulator of M1 and IL4, a stimulator of M2 polarisation induced FGFR1 and 2. LPS induced expression of FGFR1 and 2 in BMDM, however IL4 only induced FGFR1 (Fig. 2g). Thus tumour cells can influence macrophages to induce FGFR expression.

12To identify the sources of FGF2, we performed flow cytometry analysis for FGF2 on cells isolated from the tumour. Macrophages expressed FGF2 abundantly (83.3%), while fewer MDSCs or granulocytes expressed FGF2, 9.7% and 29.9% respectively. In contrast, FGF2 was expressed in <4% of T cells (Fig. 3a). TAMS express several hundred folds more Fgf2 RNA than BMDM. Of the cultured tumour cells, only MC38 expressed detectable Fgf2 RNA and this was several hundred folds less than the amounts from TAMs (Fig. 3b). It should be noted that both antibody staining and RNA analysis detect FGF2 high molecular weight forms as well as FGF2LMW. To further assess Fgf2 expression in cancers, we analysed the relationship of Fgf2 expression to immune subpopulation markers in human CRC using GSEA analysis (Fig. 3c). Macrophage and granulocyte rich tumours, as identified by gene expression signatures, correlated with increased Fgf2 expression, whereas CD8+ T cells, CD4+ T cell, Th1 cells and Th2 cells showed no correlation (Fig. 3c). These data are consistent with murine studies identifying myeloid cells as a major source of FGF2LMW.

13A shift in TAM polarisation, without altered TAM number, can have profound effects on tumour growth,. Therefore, we assessed TAM polarisation in Fgf2LMW−/− mice by flow cytometry and RNA analysis (Fig. 4a). iNOS is well described as a marker of M1 polarisation, while CD206 is an M2 marker. TAMs from Fgf2LMW−/− mice had a significant increase in iNOS expression compared with TAMs from WT mice, while over 90% expressed CD206 in both genotypes illustrating the complexity of macrophage polarization (Fig. 4a). We then isolated TAMs from WT and Fgf2LMW−/− mice 10 days after tumour cell inoculation and analysed RNA expression (Fig. 4b). TAMs isolated from Fgf2LMW−/− mice had a significant increase in M1 or inflammatory markers compared with those from WT mice, including Il6, Ifnγ, Tnfα and iNos, and H2-Eα (MHC II) (Fig. 4b). TAMs isolated from Fgf2LMW−/− mice also had decreased expression of the M2 markers, Ym1 and Ym2 (Fig. 4b). These data demonstrate marked alterations in the polarisation of TAMs from tumours in Fgf2LMW−/− mice compared with those from WT mice.

14We evaluated cytokine induction after exposure of BMDM from Fgf2LMW−/− or WT mice to polarisation stimuli, LPS (M1) or IL4 (M2). Without stimulation, Fgf2LMW−/− BMDM had higher levels of the pro-inflammatory cytokines, Cxcl1, Il1β, Il6 and Tnfα, and decreased Ym2, a M2 marker compared with WT BMDM (Fig. 4c). Following LPS stimulation, increases in Cxcl1, Cxcl2, Il1β and Il6 RNA expression in Fgf2LMW−/− BMDM and decreases in Ym1 and Ym2 were similar in both genotypes (Fig. 4c). IL4 treatment led to a reduction of iNos in Fgf2LMW−/− BMDM and WT BMDM, and an increase in Ym1 and Ym2 (Fig. 4c). Thus the overall levels reflected the presence or absence of FGF2LMW, but the changes after stimulation were similar for both.

15We asked whether exposure to FGF2 in culture altered macrophage cytokine expression. Addition of rFGF2 to BMDM from either WT or Fgf2LMW−/− mice resulted in induction of Cxcl1,2 and Nos2 (Supplementary Fig. 3a, b). Because exposure of BMDM to CM induced FGFRs, we then added rFGF2 after exposure of WT or Fgf2LMW−/− BMDM to CM, resulting in the induction of Cxcl1,2, and Ym1,2 (Supplementary Fig. 3a, b). While the results in tissue culture not surprisingly do not fully replicate the expression patterns in vivo, these experiments suggest that FGF2 alters the phenotypes of TAMs, and may be critical in allowing macrophages to generate a pro-tumour response.

16To ask whether macrophages affect tumour growth, we co-injected BMDM with tumour cells (Supplementary Fig. 4a). BMDM co-injected with MC38 cells subcutaneously did not alter the tumour growth rate. However, co-culture of BMDM with MC38 cells prior to injection, led to a significant and sustained increase in tumour growth (Fig. 5a). Co-culture of BMDM with tumour cells led to increased expression of iNOS and CD206, and Il1α, Il1β, Il6 and Tgfβ in the BMDM (Fig. 5b; Supplementary Fig. 4b). To determine whether FGF2LMW deficiency in BMDM influenced tumour growth, we co-injected tumour cells with uneducated WT or Fgf2LMW−/− BMDM subcutaneously. We used two different ratios of tumour cells to BMDM to examine dose response. Co-injection of tumour cells with WT BMDM did not affect tumour growth at a 1:1 or 1:4 ratio (Fig. 5c). In contrast, co-injection of Fgf2LMW−/− BMDM with tumour cells delayed tumour growth in a dose-dependent manner (Fig. 5c, d). Thus macrophage genotype and conditioning affected tumour growth.

17To ask whether these macrophages altered the immune infiltrate, we collected the subcutaneous tumours 14 days post-inoculation and analysed the tumour infiltrate (Fig. 5e). Compared with control tumours, co-injection with Fgf2LMW−/− BMDM resulted in an increase in the proportion of CD8+ T cells, whereas co-injection with WT BMDM did not alter the tumour infiltrate (Fig. 5e). To assess the contribution of an adaptive immune response, we repeated our co-injection experiments (1:1 ratio) in immunodeficient SCID mice, which lack mature T and B cells (Fig. 5f). Following co-injection of Fgf2LMW−/− BMDM with tumour cells in immunodeficient SCID mice, we observed a similar tumour growth delay, demonstrating that the tumour growth delay resulting from Fgf2LMW−/− BMDMs is in part independent of T cells (Fig. 5f).

18FGF2 is only sporadically reported as increased in human cancers, but radiotherapy has been shown to increase expression of FGF2 in human rectal and cervical cancers,,. To determine whether this was the case in our models, we assessed FGF2LMW expression by Western blotting of lysates from irradiated subcutaneous tumours derived from CRC cell lines; human SW1222 and HT29, and murine MC38. We used fractionated radiation at 2 Gy in analogy to the treatment of human cancers, although at lower total doses. Following fractionated radiation of nine fractions of 2 Gy, the amount of FGF2LMW in all three tumour models was increased (Fig. 6a, b). There are no antibodies that distinguish FGF2LMW from FGF2HMW because all FGF2HMW include the entire low-molecular weight protein. Thus immunostaining will capture FGF2HMW. Recognising this important caveat, that staining could also indicate FGF2HMW, we applied immunohistochemistry to locate and quantitate the FGF2 in the irradiated tumours (Fig. 6c, d). MC38 FGF2 staining intensity was increased in irradiated tumours compared with unirradiated (Fig. 6c). In both irradiated and unirradiated tumours FGF2 staining was noted in most F4/80+ macrophages, further suggesting that TAMs are a major source of FGF2. A similar pattern was seen in SW1222 tumours (Fig. 6c). In both cases staining was seen in other cell types as well as in areas that are likely extracellular. HT29 had a higher level of FGF2 staining in cell types other than F4/80 positive cells and there was less increase in overall FGF2 staining after irradiation, although absolute levels were high and most of the F4/80 positive staining areas also stained for FGF (Fig. 6c, d). The staining in other cells might reflect FGF2HMW expression in tumour cells. MC38 tumours in Fgf2LMW−/− mice, control or irradiated failed to show any FGF2 staining of tumour cells or of macrophages further suggesting that the contribution of the tumour cells to FGF2 is minimal for MC38 cells (Fig. 6e). Thus, as reported in human rectal and cervical cancers–, radiotherapy led to increased total tumour content of FGF2LMW, and FGF2 was found in TAMs.

19In Fig. 1 tumours generated after a subcutaneous injection of 1 × 104 MC38 cells resulted in an immune response leading to decreased growth and rejection. Because higher numbers of inoculated cells can result in diminished anti-tumour immune responses we injected 2 × 105 MC38 cells and did not see rejection or even differences in tumour growth in WT and Fgf2LMW−/− mice (Fig. 7a, Supplementary Fig. 5a). We then used these tumours to examine the response to radiation therapy. Tumours in Fgf2LMW−/− mice were substantially more responsive to radiation than the tumours in WT mice with greater growth delays and a higher percentage of cure (Fig. 7a, Supplementary Fig. 5a).

20We asked whether an anti-FGF2 blocking antibody would similarly affect the tumour response to radiotherapy. MC38 tumours in WT mice received fractionated radiation of 9 × 2 Gy after reaching 100 mm3. Anti-FGF2 blocking antibody was administered every second day for 4 weeks. The anti-FGF2 antibody itself did not affect tumour growth in unirradiated mice. Mice whose tumours received radiation reached endpoint 12 days post-irradiation, while the addition of anti-FGF2 antibody led to a significant growth delay with mice reaching the experimental endpoint on average 24 days post-irradiation (Fig. 7b; Supplementary Fig. 5b). Thus similar to the results with tumours in Fgf2LMW−/− mice, the addition of anti-FGF2 blocking antibody delayed growth of irradiated MC38 tumours.

21We asked what effect these treatments might have on human tumour cell lines. We used both a radiation sensitive tumour from SW1222 cells and a more resistant cell line HT29 in immunosuppressed mice administering the same radiation dose as above. In both cases administration of the anti-FGF2 antibody had no effect on tumour growth in unirradiated mice. However, addition of the anti-FGF2 blocking antibody significantly enhanced the efficacy of irradiation (Fig. 7c, d; Supplementary Fig. 5c, d). For SW1222 tumours, the more radiosensitive tumours, 9 of 11 mice that received combination therapy survived for over 170 days, and 6 of 11 mice had complete tumour regression by 210 days, compared with 1 of 8 mice in the irradiated group (Fig. 7c; Supplementary Fig. 5c). For HT29, irradiation alone significantly delayed tumour growth, with mice reaching endpoint 35 days post-treatment, compared with 40 days for mice receiving combination therapy, a significant but smaller prolongation (Fig. 7d Supplementary Fig. 5d). Administration of the anti-FGF2 blocking antibody also greatly delayed tumour growth of irradiated MC38 tumours in syngeneic, immunocompetent mice. Thus, in both immunosuppressed and immunocompetent models given the same dose to more or less radiosensitive models, addition of anti-FGF2 blocking antibody during radiotherapy enhanced the growth delay and increased the incidence of long-term survival.

22We asked whether we could demonstrate FGF2 mediated autocrine growth factor effects. Addition of antibody to FGF2 or a pan-FGFR inhibitor (BGJ398) did not reduce cellular viability, proliferation or clonogenic survival after radiation (Supplementary Figs. 6, 7a, b). Further even though the cancer cell lines used in this study variably expressed FGFR1-4 (Supplementary Fig. 7c), neither BGJ398 nor recombinant FGF2 in tissue culture altered the best described downstream mediators of FGFR signalling, pERK and pAKT (Supplementary Fig. 7d, e). Thus we failed to find evidence of FGF2 mediated autocrine growth factor signalling by the tumour cell lines that we used.

23We asked whether the FGF2 blocking antibody led to effects on tumour vascularity. Here the data were model specific. FGF2 blocking antibody reduced vascularity slightly in the MC38 model, but not in the SW1222 model (Supplementary Fig. 8). In neither case did it affect tumour growth (Fig. 7a–c) or distribution of vessel size (Supplementary Fig. 8b). Radiation reduced vascularity in both models. Vascular size was notably reduced by FGF2 blocking antibody in irradiated SW1222 but not in MC38 tumours (Supplementary Fig. 8c). When using a different measure, perfused vessel volume, to evaluate vascularity, MC38 tumour vascularity was unaffected by anti-FGF2 antibody, but was reduced after irradiation. Further tumours in Fgf2LMW−/− mice had approximately the same vascular density as tumours in WT mice. Irradiation reduced the vascular density in Fgf2LMW−/− mice and vascular volume (Supplementary Fig. 9a, b). Thus whilst anti-angiogeneic effects might play a role, this effect did not appear to be substantial or generalisable.

24Consistent with many reports, we found irradiated tumours had higher proportions of CD11b+F4/80+ TAMs than controls (Fig. 8a, c). Administration of anti-FGF2 antibody marginally reduced (without statistical significance) the proportion of macrophages in the non-irradiated tumours, but did not alter the increase in CD11b+F4/80+ cells following irradiation (Fig. 8a–c). Although anti-FGF2 antibody did not influence the proportion of TAMs, it had a profound effect on macrophage polarisation after irradiation (Fig. 8d–f). The iNOS+/CD206+ (M1/M2) ratio of TAMs decreased with irradiation in the SW1222 tumours, but was unchanged in the other two models (Fig. 8d–f). The effect of the anti-FGF2 antibody alone was also variable. However, combination of the radiotherapy and anti-FGF2 antibody consistently led to an increased iNOS+/CD206+ macrophage ratio (Fig. 8d–f). Whilst MC38 cells were tested in syngeneic mice, the combination of irradiation and anti-FGF2 antibody also effectively prolonged survival of immunosuppressed mice bearing SW1222 and HT29 subcutaneous tumours. Thus, blocking FGF2 led to changes in TAM polarisation towards the M1 spectrum and correlated with enhanced growth delay after radiotherapy.

25Tumour-associated macrophages (TAMs) have the capacity for both pro- and anti-tumourigenic functions,. Here we show that FGF2 in the tumour microenvironment can be a potent factor in directing macrophages towards a more pro-tumourigenic state. FGF2 in cancer has previously been implicated as an angiogenic factor,, with the caveat that increased FGF2 is not always associated with increased vascularity. FGF2 has not previously been implicated in the regulation of macrophages, nor in tumour immunity,.

26In our experiments, cancer cells including MC38 at lower innocula failed to generate continued tumour growth in Fgf2LMW−/− mice with tumour regression dependent on T cells. In these tumours TAMs were the predominant immune cells that expressed FGF2 and its receptors. Although the proportion of macrophages infiltrating the tumours was equivalent in WT and Fgf2LMW−/− mice, the nature of these TAMs was substantially different. Macrophage polarisation or activation can lead to a complex variation of expression patterns and functions,,. These range from inflammatory, anti-tumourigenic phenotypes (M1) to pro-tumourigenic and immunosuppressive functionality (M2). In general, TAMs have been described as more M2 in nature,,. TAMs from Fgf2LMW−/− mice expressed many characteristic pro-inflammatory cytokines and markers compared with WT TAMs, and Fgf2LMW−/− BMDM suppressed tumour growth after co-injection. This suppressive effect was associated with enhanced infiltration of T cells in immunocompetent mice, but was also evident in immunosuppressed mice. This enforces the concept that FGF2 mediates tumour growth through alteration of TAMs, both dependent and independent of adaptive immunity. In addition, other cell types in the tumour microenvironment, such as fibroblasts are also likely to be affected by the Fgf2LMW−/− genotype and the altered phenotype of TAMs almost certainly includes indirect effects.

27Macrophages have multiple effects on tumour growth, some of which can involve tumour immunity, with or without an adaptive immune response. For example, CSF1 which acts as both a chemotactic and survival factor for macrophages also promotes M2-like polarisation. As a result, in some glioblastoma models, inhibition of CSF1 led to a shift in TAM polarisation away from pro-tumourigenic phenotypes resulting in tumour regression independent of adaptive immunity. In other models, inhibition of CSF1 resulted in an enhanced immune response. Furthermore, inhibition of PI3Kγ blocked M2 polarisation of macrophages, promoted T cell recruitment, and enhanced anti-tumour immunity,. Here we showed that co-injection of BMDM conditioned by tumour cells had a tumour growth promoting effect. We also found that BMDM deficient in Fgf2LMW−/− mice have an anti-tumour effect. These actions were both adaptive immune dependent and independent.

28Radiotherapy is known to stimulate adaptive immunity to tumours–, but nonetheless an effective anti-tumour response often fails to occur even after administration of immune checkpoint therapy. Macrophage recruitment and polarisation after irradiation of tumours is one factor contributing to immunosuppression, which can counteract the immune stimulatory effect of irradiation,. It should be noted that alteration of macrophage recruitment and polarization has been shown to radiosensitize tumours. Agents such as anti-CSFR1 antibody and SDF1 inhibition have been used in this way,,,. The dose of radiation makes a difference,. Klug et al. showed that at relatively low doses, up to 2 Gy, radiation led to improved T cell infiltration into tumours due to induction of NOS2 expressing macrophages. Some of these effects were due directly to irradiation of the macrophages. In our hands at higher doses a similar macrophage phenotype also was influenced by the absence or blocking of FGF2. We observed an increase in FGF2 following irradiation of tumours in mice similar to those described in several clinical reports–,,. Blocking FGF2 with a specific antibody led to diminished tumour regrowth after irradiation that was associated with an increase in M1 polarisation of TAMs. It should be noted that there are at least 22 human FGFs. Blocking only FGF2 is likely to have very different effects than blocking less specifically the FGF-FGFR signalling pathways. Treatment with the blocking anti-FGF2 antibody did not affect tumour growth or macrophage polarisation unless irradiation had been applied, similar to the tumours formed from high innocula in Fgf2LMW−/−mice. We failed to find evidence that FGF2 was acting as an autocrine growth factor for these cancer cells. Macrophages influence tumour angiogenesis. FGF2 certainly might affect angiogenesis directly in these models, but the effect could also be indirect through reprogramming of macrophages. In our hands blocking FGF2 or its absence did not have a generalisable effect on tumour vascular density before or after radiation. Inhibition of tumour growth after irradiation occurred in both immunocompetent and immunosuppressed mice. The extent of the additional effect of the anti-FGF2 antibody correlated with the extent of the tumour response to radiation alone. These data are consistent with previous reports showing inhibition or depletion of macrophages after irradiation leads to prolonged tumour growth delay or in some cases augments immune checkpoint therapy,,,.

29Here, we directly associate TAMs with increased tumour growth based on experiments showing enhanced tumour growth after co-injection of cancer cells with pre-conditioned BMDMs. Macrophages were the only immune cell population in tumours to abundantly expression FGFR1 or 2, and in tissue culture, we showed that tumour cells can induce the expression of FGFR1 and 2 in BMDM. Furthermore, FGF2 levels are increased in the tumour microenvironment following irradiation in vivo. Collectively, these findings suggest that TAMs in the tumour microenvironment are ready to engage with FGF2 in the irradiated tumour microenvironment leading to reprogramming to generate a more pro-tumourigenic milieu. These TAMs can then contribute to tumour growth in both an immune dependent and independent fashion.

30Our work suggests that macrophage polarisation could be a component driving delayed tumour growth and tumour regression in Fgf2LMW−/− mice. It also suggests that FGF2 in the tumour microenvironment is an important regulator of macrophage differentiation, particularly during radiotherapy. Further recognition of factors, which contribute to TAM polarisation could lead to novel therapeutic strategies. In non-cancer models, effects on macrophages by FGF2 have not been directly described. However, enhanced leucocyte recruitment directed by FGF2, and promotion of autoimmune arthritis are both suggestive of potential macrophage involvement. FGF2 deficiency leads to enhanced colitis in murine models, demonstrating the capacity of FGF2 to mediate inflammation. Furthermore, FGF2 supports wound healing, a process associated with a rapid influx of myeloid cells, and depletion of FGF2 delays wound healing. Even though effects on macrophages have not been described directly in these settings, our work introduces these possibilities and raises additional questions about effects on fibroblasts, other cell types and other more complex indirect actions. Overall our work defines FGF2 as a key modulator of macrophage polarisation in tumours and demonstrates that FGF2, as well as other factors which regulate macrophage activity, can be targeted during radiotherapy.

31All methods are available in the Supplementary Information methods section.

32Further information on research design is available in the Nature Research Reporting Summary linked to this article.